July 20 - 21 two days forum
As part of the market entry program funded by the German Federal Ministry for Economic Affairs and Climate Action, nine German companies of the German biomedical sector are taking part in a digital business matching program in Japan.
The program includes a two-day online forum. The aim of the event is to promote German-Japanese cooperation in the biomedical industry and to promote the German companies in the biomedical industry in Japan. German and Japanese companies will introduce themselves and their products. The German Federal Ministry will introduce its support measures for the matchmaking of German and Japanese biomedical companies, while biomedical associations and companies will present their activities.
Date
[Day 1] 20 July 2022 (Wed) 15:00-17:10 JST/ 08:00-10:10 CEST
[Day 2] 21 July 2022 (Thu) 15:00-17:30 JST/ 08:00-10:30 CEST
Program
[Day 1] Life science
[Day 2] Research & Development
The programme is subject to change at any time.
Participating Companies
[Day 1] 20 July 2022 (Wed)
| [Day 2] 21 July 2022 (Thu)
|
Click on the company name to link to the company website.
Company | Introduction |
---|---|
FamiCord Deutschland GmbH | FamiCord Group, the leading stem cell bank in Europe and number 3 worldwide, is a publicly traded biotech group consisting of European biotech companies Vita 34 (Germany), P.B.K.M. (Poland), Crioestaminal (Portugal), Smart Cells (UK) and over 30 other subsidiaries. Founded in 2002, FamiCord Group is present in over 35 countries in Europe and the Middle East. The group deals with the storage of biological material and the manufacture, development, and approval of cell therapeutics for clinical use. More than 850,000 cryopreserved umbilical cord blood and tissue deposits and more than 4,200 patients treated with stem cells in clinical studies, experimental and standard therapies testify to the extraordinary expertise in the field of stem cell banking and clinical application. FamiCord Deutschland GmbH deals with the manufacture, development, and approval of ATMP for clinical use in humans. |
FGK Clinical Research GmbH | FGK Clinical Research is a full-service CRO based in Germany, with its headquarters in Munich, a branch office in Berlin, and subsidiaries in Czech Republic, Poland, and Hungary. Since 2002, FGK has been managing clinical studies of phases I to IV from planning to the final report throughout Europe, specializing in cooperation with small to medium-sized biotech, medical device or pharmaceutical companies. The management of FGK sees their innovative therapy approaches as a special challenge. FGK has experience in every important medical indications, including particular focuses in oncology, cardiology, neurology, dermatology, and gastroenterology. The extensive experience of its 200 employees and an owner-managed company structure with flat hierarchies enable FGK to support these complex projects flexibly and personally. At the same time, FGK is constantly expanding its expertise and keeps pace with the increasing digitalization in the field of clinical studies. |
Green Elephant Biotech GmbH | Green Elephant Biotech GmbH, based in Giessen (Germany), was formed in 2021 as a spin-off from the Technical University of Hesse (THM) in the field of bioprocess technology. The company was founded by Felix Wollenhaupt and Dr. Joel Eichmann with the aim of producing laboratory supplies from sustainable materials and thus supporting research and production companies in the biotech and pharmaceutical industries in reducing their CO2 emissions. |
KIEFEL GmbH | Kiefel GmbH is a dependable partner for innovative & reliable production machine solutions for the medical, pharmaceutical, and bioprocess industry, which demands highest standards. Kiefel's systems for producing bioprocess-, pharmaceutical- and medical-specialty bags, as well as special application units ensure high-quality products in these important sectors. |
LenioBIO GmbH | LenioBio is a protein expression platform company committed to advancing transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell. |
Lipotype GmbH | Lipotype is the leading lipidomics provider and your access to lipids and lipid metabolism data. Our mass spectrometry-based platform can be applied to all biological samples and covers more than 4200 lipids – the broadest lipidomics coverage. |
MANNIN GmbH | Mannin GmbH is a small biotech company developing therapeutics (based on small and large molecules) for vascular diseases using the Tie-2 pathway. Our main fields of indications are Acute Respiratory Diseases (ARDS), Glaucoma, kidney diseases. |
Raumedic AG | As a partner of the international medical technology and pharmaceutical industry, RAUMEDIC develops and produces customized polymer components for customers, including tubing, catheters, and molded parts as well as complex groups of components and systems for a wide range of diagnostic and therapeutic uses. |
4GENE GmbH | 4GENE was founded in 2017 and is based in Germany in Freising and Stuttgart. The Development of our innovative technology platform for small molecule glycosylation lasted from 2017 to 2021. To demonstrate the flexibility and efficiency of the platform, we have developed 50 glucosides of common molecules for pharmaceutical, cosmetic and industrial customers. Today, 4GENE is a CDMO and develops and produces specific glucosides for its customers. |
Organizers
A program of
German Federal Ministry for Economic Affairs and Climate Action
Organized by
German Chamber of Commerce and Industry in Japan
DREBERIS GmbH
Professional Support
German Trade & Invest (GTAI), Exportinitiative Gesundheitswirtschaft, BioM Biotech Cluster Development GmbH, Biosaxony e.V., Cluster Biotechnology Bavaria, City of Kobe, The Forum for Innovative Regenerative Medicine (FIRM), Japan Bioindustry Association (JBA), Japan Pharmaceutical Manufacturers Association (JPMA), The Pharmaceutical Society of Japan (PSJ)
Denise Schieberl
ConsultantDEinternational Business Services